stockrowSotera Health Company
SHC Healthcare Diagnostics & Research
Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024.
- Revenue
- +4.36%
- EPS
- +20.1%
- Free cash flow
- +65.0%
- Total debt
- +0.14%
Quarter to September 2026, against a year earlier
Follow SHC
Alert me
Sotera Health Company (SHC) Shares outstanding
Sotera Health Company's shares outstanding at the end of fiscal 2025 was $286.4M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $289.2M. Over the past ten years it has ranged from $232.4M (fiscal 2019) to $286.4M (fiscal 2025) — the current reading is the highest in ten years. Sotera Health Company ranks 5th of 49 Diagnostics & Research companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $286.4M | 0.53% |
| FY2024 | $284.9M | 0.59% |
| FY2023 | $283.2M | 1.12% |
| FY2022 | $280.1M | 0.26% |
| FY2021 | $279.4M | 17.54% |
| FY2020 | $237.7M | 2.28% |
| FY2019 | $232.4M | 0.00% |
| FY2018 | $232.4M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $289.2M | 0.37% |
| Jun 2026 | $288.1M | 0.18% |
| Mar 2026 | $287.6M | 0.42% |
| Dec 2025 | $286.4M | (0.11%) |
| 24 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SHC Sotera Health Company | $289.2M |
| QGEN QIAGEN N.V. compare | $207.8M |
| ADPT Adaptive Biotechnologies Corporation compare | $186.9M |
| NEO NeoGenomics, Inc. compare | $128.6M |
| VCYT Veracyte, Inc. compare | $82.8M |
| RDNT RadNet, Inc. compare | $78.7M |
| CDNA CareDx, Inc. compare | $55.0M |
| BLLN BillionToOne, Inc. compare | $53.7M |
| GRAL GRAIL, Inc. compare | $46.8M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on SHC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement